L12.3
Acquired epidermolysis bullosa
Clinical Classification Guidelines
Excludes Type 1
- epidermolysis bullosa (congenital) (Q81.-)
Medical Intelligence & Overview
Acquired epidermolysis bullosa (EB) is a rare skin condition characterized by fragile skin that blisters or tears easily, often as a result of an autoimmune response or other acquired causes. Unlike inherited forms of EB, which are present from birth, the acquired type develops later in life due to underlying health issues or external factors. This condition leads to painful skin lesions, increased risk of infection, and potentially significant impacts on quality of life. Proper understanding of its causes, symptoms, diagnosis, and management options can aid in better awareness and support for affected individuals.
Causes & Symptoms
Clinical Causes: Autoimmune disorders where the body mistakenly attacks structural components of the skin Certain medications triggering an immune response that damages skin layers Underlying diseases such as lupus erythematosus or other systemic autoimmune conditions Exposure to external trauma or chemical irritants that weaken skin integrity Rare cases where cancer or other systemic illnesses lead to acquired skin fragility
Key Symptoms: Blistering of the skin that appears suddenly and can occur anywhere on the body Fragile skin that tears, rips, or erodes easily from minor injuries or friction Painful skin lesions and open sores Scarring and disfigurement in some cases Possible mucous membrane involvement affecting the mouth, eyes, or genitals Itching and discomfort around affected areas Signs of infection, such as redness, swelling, or pus
Diagnostic & Treatment
Diagnosis Path: Diagnosis of acquired epidermolysis bullosa involves a combination of clinical evaluation and laboratory tests. Healthcare providers will review the patient’s medical history and conduct a physical examination focusing on skin lesions. Confirmatory tests may include skin biopsies with immunofluorescence microscopy to detect immune deposits or structural abnormalities. Blood tests to identify autoimmune markers or underlying conditions can also aid in establishing the diagnosis. Since acquired EB can resemble other blistering diseases, accurate diagnosis is essential for appropriate management.
Treatment Protocols: Management of acquired epidermolysis bullosa centers on controlling symptoms, preventing infections, and addressing underlying causes. Treatment strategies may include:
Clinical Advice & FAQs
Billing Guidance
Is L12.3 a billable ICD-10 code?
Yes, L12.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report L12.3?
Clinical documentation must specify the nature of Acquired epidermolysis bullosa and any associated comorbidities for accurate reporting.
Cite this Clinical Reference